The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 18, 2020

Filed:

Dec. 02, 2015
Applicants:

The University of Tokyo, Tokyo, JP;

Idac Theranostics, Inc., Tokyo, JP;

Inventors:

Kouji Matsushima, Tokyo, JP;

Satoshi Ueha, Tokyo, JP;

Satoru Ito, Tokyo, JP;

Shoji Yokochi, Tokyo, JP;

Yoshiro Ishiwata, Tokyo, JP;

Assignees:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/00 (2006.01); G01N 33/50 (2006.01); C12Q 1/68 (2018.01); G01N 33/49 (2006.01); C12Q 1/04 (2006.01); G01N 33/68 (2006.01); G01N 33/48 (2006.01);
U.S. Cl.
CPC ...
G01N 33/5011 (2013.01); C12Q 1/04 (2013.01); C12Q 1/68 (2013.01); G01N 33/48 (2013.01); G01N 33/49 (2013.01); G01N 33/68 (2013.01); G01N 2333/525 (2013.01); G01N 2333/57 (2013.01); G01N 2333/70503 (2013.01); G01N 2333/70517 (2013.01); G01N 2333/70553 (2013.01); G01N 2333/70578 (2013.01); G01N 2333/70589 (2013.01); G01N 2333/70596 (2013.01);
Abstract

Means that enables monitoring of an anticancer effect of an anti-CD4 antibody or an anticancer drug targeting an immune checkpoint is disclosed. The method for testing a therapeutic effect of a cancer therapy of the present invention is a method for testing a therapeutic effect of an anticancer drug comprising as an effective ingredient an anti-CD4 antibody or an anticancer drug targeting an immune checkpoint, which method comprises investigation of expression of (1) at least one immune checkpoint receptor, (2) CD8, and (3) at least one cell surface molecule selected from the group consisting of CD44 and CD45RO, on T cells using a sample derived from a patient who received the anticancer drug. Induction of a T cell population which is positive for the immune checkpoint molecule (1) and positive for CD8, and which shows high expression of CD44 and/or high expression of CD45RO, indicates that said anticancer drug is producing a therapeutic effect in said patient.


Find Patent Forward Citations

Loading…